Brief: ABVC Biopharma Submits Vitargus Phase II Study Plan To Australia HREC
June 16 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA SUBMITTED VITARGUS® PHASE II STUDY PLAN TO
AUSTRALIA HREC
* ABVC BIOPHARMA - PHASE II STUDY IS TARGETED TO BEGIN IN
AUGUST
OF 2022 IN BOTH AUSTRALIA AND THAILAND AND IS EXPECTED TO BE
COMPLETED BY END OF 2023
Source text for Eikon: ID:nGNXbDhBtm
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon